<DOC>
	<DOC>NCT03083821</DOC>
	<brief_summary>A Pharmacokinetics study of Baraclude in a real world clinical setting in Japan.</brief_summary>
	<brief_title>A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. Participants with chronic hepatitis B (CHB) (excluding participants with a superinfection) who have been confirmed to have CHB. Participants who are being treated with 0.5 mg daily Baraclude for a minimum of 10 consecutive days prior to the study enrollment. Body mass index (BMI) of 18.5 to 30 kg/m2 (BMI = body weight [kg]/height [m]2) Current or recent (within 3 months of Baraclude administration) gastrointestinal disease that could impact upon the absorption of study drug. Any gastrointestinal surgery that could impact upon the absorption of study drug. Donation of blood to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration (within 2 weeks for plasma only). Other protocol defined inclusion/exclusion criteria could apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>